CN1703407A - 脂肪酸酰胺水解酶抑制剂 - Google Patents

脂肪酸酰胺水解酶抑制剂 Download PDF

Info

Publication number
CN1703407A
CN1703407A CNA2003801009944A CN200380100994A CN1703407A CN 1703407 A CN1703407 A CN 1703407A CN A2003801009944 A CNA2003801009944 A CN A2003801009944A CN 200380100994 A CN200380100994 A CN 200380100994A CN 1703407 A CN1703407 A CN 1703407A
Authority
CN
China
Prior art keywords
subunit
fatty acid
acid amide
solution
oxazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801009944A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·博格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN1703407A publication Critical patent/CN1703407A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA2003801009944A 2002-10-08 2003-10-08 脂肪酸酰胺水解酶抑制剂 Pending CN1703407A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41724702P 2002-10-08 2002-10-08
US60/417,247 2002-10-08

Publications (1)

Publication Number Publication Date
CN1703407A true CN1703407A (zh) 2005-11-30

Family

ID=32093990

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801009944A Pending CN1703407A (zh) 2002-10-08 2003-10-08 脂肪酸酰胺水解酶抑制剂

Country Status (15)

Country Link
US (1) US7662971B2 (https=)
EP (2) EP2093220A3 (https=)
JP (1) JP4628789B2 (https=)
KR (1) KR20050070041A (https=)
CN (1) CN1703407A (https=)
AT (1) ATE431342T1 (https=)
AU (1) AU2003275493A1 (https=)
BR (1) BR0314980A (https=)
CA (1) CA2501575A1 (https=)
DE (1) DE60327640D1 (https=)
EA (1) EA008767B1 (https=)
ES (1) ES2325686T3 (https=)
MX (1) MXPA05003762A (https=)
WO (1) WO2004033652A2 (https=)
ZA (1) ZA200501837B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459202A (zh) * 2009-05-18 2012-05-16 无限药品股份有限公司 作为脂肪酸酰胺水解酶的抑制剂的异噁唑啉
CN102858338A (zh) * 2010-01-28 2013-01-02 默沙东公司 治疗疼痛及其它适应症的药物组合物
CN102964311A (zh) * 2011-09-01 2013-03-13 大丰海嘉诺药业有限公司 一种合成4-甲基-5-烷氧基噁唑的方法
CN105399731A (zh) * 2008-12-24 2016-03-16 比亚尔-珀特拉和Ca股份公司 药物化合物

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
BR0314980A (pt) 2002-10-08 2005-08-09 Scripps Research Inst Inibidores de hidrolase de amida de ácido graxo
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
DE102004039326A1 (de) * 2004-08-12 2006-02-16 Abbott Gmbh & Co. Kg Neue medizinische Verwendungen und Verfahren
US7351724B2 (en) 2004-10-15 2008-04-01 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
EP1954137A4 (en) 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
JP2009527483A (ja) 2006-02-17 2009-07-30 ザ・スクリプス・リサーチ・インステイチユート 脂肪酸アミドヒドロラーゼの調節因子としてのオキサゾールケトン
WO2008013963A2 (en) 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
WO2008030532A2 (en) * 2006-09-08 2008-03-13 The Scripps Research Institute Substituted oxazole ketone modulators of fatty acid amide hydrolase
AU2008257154B2 (en) * 2007-05-25 2014-03-06 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
EP2161997A4 (en) * 2007-05-31 2011-04-06 Scripps Research Inst TRICYCLIC INHIBITORS OF FATTY ACID AMIDHYDROLASE
CA2714743C (en) * 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US20110184026A1 (en) * 2008-06-19 2011-07-28 Boger Dale L C4-substituted alpha-keto oxazoles
WO2010005572A2 (en) * 2008-07-09 2010-01-14 The Scripps Research Institute Alpha-keto heterocycles as faah inhibitors
EP2321288B1 (en) 2008-08-04 2014-03-19 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of faah
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
ES2626246T3 (es) 2009-09-09 2017-07-24 Sumitomo Dainippon Pharma Co., Ltd. Derivado de 8-oxodihidropurina
CA2782797C (en) 2009-10-02 2018-08-07 Avexxin As Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles
US20120225097A1 (en) 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
US9006433B2 (en) 2010-04-21 2015-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
ES2888231T3 (es) * 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
ES2648188T3 (es) * 2012-02-17 2017-12-29 Epitech Group S.P.A. Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
WO2015066277A1 (en) 2013-11-01 2015-05-07 Merial Limited Antiparisitic and pesticidal isoxazoline compounds
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US20160244860A1 (en) * 2015-02-20 2016-08-25 Cytec Industries Inc. Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP3095787A1 (en) * 2015-05-22 2016-11-23 Universiteit Leiden Pharmaceutically active compounds as dag-lipase inhibitors
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
JP7531351B2 (ja) 2019-11-13 2024-08-09 東京エレクトロン株式会社 基板処理方法、基板処理装置、および基板処理システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA19269A1 (fr) * 1980-09-16 1982-04-01 Lilly Co Eli Perfectionnement relatif a des derives de n-arylbenzamides .
US5646289A (en) * 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
BR0314980A (pt) 2002-10-08 2005-08-09 Scripps Research Inst Inibidores de hidrolase de amida de ácido graxo

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105399731A (zh) * 2008-12-24 2016-03-16 比亚尔-珀特拉和Ca股份公司 药物化合物
CN102459202A (zh) * 2009-05-18 2012-05-16 无限药品股份有限公司 作为脂肪酸酰胺水解酶的抑制剂的异噁唑啉
CN102459202B (zh) * 2009-05-18 2015-11-25 无限药品股份有限公司 作为脂肪酸酰胺水解酶的抑制剂的异噁唑啉
CN102858338A (zh) * 2010-01-28 2013-01-02 默沙东公司 治疗疼痛及其它适应症的药物组合物
CN102964311A (zh) * 2011-09-01 2013-03-13 大丰海嘉诺药业有限公司 一种合成4-甲基-5-烷氧基噁唑的方法
CN102964311B (zh) * 2011-09-01 2016-03-09 大丰海嘉诺药业有限公司 一种合成4-甲基-5-烷氧基噁唑的方法

Also Published As

Publication number Publication date
US20060111359A1 (en) 2006-05-25
ES2325686T3 (es) 2009-09-14
AU2003275493A1 (en) 2004-05-04
BR0314980A (pt) 2005-08-09
MXPA05003762A (es) 2005-07-22
ATE431342T1 (de) 2009-05-15
EA200500633A1 (ru) 2005-10-27
EP2093220A3 (en) 2009-11-11
ZA200501837B (en) 2006-06-28
DE60327640D1 (https=) 2009-06-25
WO2004033652A2 (en) 2004-04-22
CA2501575A1 (en) 2004-04-22
WO2004033652A3 (en) 2004-09-16
EA008767B1 (ru) 2007-08-31
EP2093220A2 (en) 2009-08-26
JP2006502229A (ja) 2006-01-19
US7662971B2 (en) 2010-02-16
KR20050070041A (ko) 2005-07-05
EP1549624A4 (en) 2006-09-20
JP4628789B2 (ja) 2011-02-09
EP1549624A2 (en) 2005-07-06
EP1549624B1 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
CN1703407A (zh) 脂肪酸酰胺水解酶抑制剂
JP4931893B2 (ja) Ｐｐａｒ活性化化合物及びこれを含有する医薬組成物
TWI440633B (zh) Activator of Activated Receptors for Peroxisome Producers
CN1235870C (zh) 苯基杂烷基胺衍生物的新应用
JP5698666B2 (ja) Ｆａａｈの阻害剤として有用なオキサゾール誘導体
CN1146204A (zh) 噁唑类杂环芳香族化合物及其用途
CN1251099A (zh) 作为β3激动剂治疗糖尿病和肥胖症的三唑苯磺酰胺类
EA200901662A1 (ru) Агонисты фарнезоидного х-рецептора
CN1328550A (zh) 作为前列腺素e2激动剂或拮抗剂的噁唑化合物
CN1212622A (zh) 应用PPARα或PPARγ拮抗剂治疗X综合征
CN1894225A (zh) 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
CN1946666A (zh) 用于治疗代谢性疾病的化合物、药物组合物和方法
CN1558905A (zh) 茚满乙酸衍生物及其作为药物、中间体的用途以及制备方法
JPWO2008016175A1 (ja) ペルオキシソーム増殖剤活性化受容体の活性化剤
CN1558897A (zh) 口服抗糖尿病剂
JP4488732B2 (ja) ベンズオキサゾール化合物及びこれを含有する医薬組成物
CN1930152A (zh) 用于治疗i.a.肥胖症和糖尿病的1,3－二噁烷衍生物及其类似物
CN1870999A (zh) 炔烃ⅰ
CN1753879A (zh) 作为用于治疗2型糖尿病和动脉硬化症的ppar调节剂的3－(2－苯基－噁唑－4－基甲氧基)环己基甲氧基乙酸衍生物和相关化合物
CN1835743A (zh) 用于治疗代谢紊乱的化合物
Shibata et al. Synthesis and Structure–Activity Relationships of Novel Zwitterionic Compounds as Peroxisome Proliferator Activated Receptor α/γ Dual Agonists with Improved Physicochemical Properties
CN1845905A (zh) Ppar活性化化合物及含该化合物的医药组合物
CN100343250C (zh) 吲哚衍生物
CN1882553A (zh) 苯乙酸衍生物、其生产方法和用途
CN1886364A (zh) 选择性过氧化物酶体增殖物激活受体调节剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication